StemCell Therapy

Why Are Cats So Flexible? This Body Part Is Key  Inverse

Follow this link:
Why Are Cats So Flexible? This Body Part Is Key - Inverse

Those pets need the same care as our dogs and cats: New Bluefield vet treats exotic animals  WVVA

Continued here:
Those pets need the same care as our dogs and cats: New Bluefield vet treats exotic animals - WVVA

Letter to the editor: As a veterinarian, I urge you to vote no on Prop 129  Summit Daily

See the article here:
Letter to the editor: As a veterinarian, I urge you to vote no on Prop 129 - Summit Daily

Weatherford vet among four appointed to state board  Weatherford Democrat

Continue reading here:
Weatherford vet among four appointed to state board - Weatherford Democrat

The Vets and BetterVet Merge to Revolutionize Pet Care with Nationwide At-Home Services  Vet Candy

Continued here:
The Vets and BetterVet Merge to Revolutionize Pet Care with Nationwide At-Home Services - Vet Candy

Struggling with high pet med costs? Canada's competition watchdog calls for more choice and affordable options  CBC.ca

Link:
Struggling with high pet med costs? Canada's competition watchdog calls for more choice and affordable options - CBC.ca

Guest opinion: Kerry Madole: Prop 129 will help us move towards ensuring all animals receive the care they need  Boulder Daily Camera

Read the original post:
Guest opinion: Kerry Madole: Prop 129 will help us move towards ensuring all animals receive the care they need - Boulder Daily Camera

This Auburn grad found an amazing alternative to vet school in Huntsville  Hville Blast

Read the original here:
This Auburn grad found an amazing alternative to vet school in Huntsville - Hville Blast

What Is Colorados Proposition 129? Here is Everything You Need to Know  Teekinship

Excerpt from:
What Is Colorados Proposition 129? Here is Everything You Need to Know - Teekinship

Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that the last patient has been enrolled in its 22-site U.S. Phase II trial for its BK polyomavirus (“BKV”)-neutralizing antibody, potravitug.

Go here to see the original:
Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant...

DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview.

More:
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that the company's third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. Skye will host a conference call to discuss its results at 1:30 p.m. PT/4:30 p.m. ET.

Link:
Skye Bioscience to Announce Third Quarter 2024 Results

CLEVELAND, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

See more here:
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:

More here:
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024.

Originally posted here:
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

Conference call to be held Monday, November 4, 2024, at 8:30 AM ET Conference call to be held Monday, November 4, 2024, at 8:30 AM ET

See the original post:
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3)1. Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised people at 72 weeks.

Continued here:
Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial

-  Completed strategic review to focus on oncology and severe liver diseases

Here is the original post:
Galecto Reports Third Quarter 2024 Financial Results

CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on November 5, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, November 5, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol "QLGN." The new CUSIP number for the common stock will be 74754R 301.

Here is the original post:
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

Press Release – No. 10 / 2024

Read this article:
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results